Enhanced sensitivity of hormone-refractory prostate cancer cells to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated cytotoxicity by taxanes

Central European Journal of Urology

Volumn 62, Issue 1, 2009, Pages 29-34

  Szliszka, Ewelina ^a   Bronikowska, Joanna ^a   Majcher, Anatol ^a   Miszkiewicz, Jerzy ^a   Krol, Wojciech ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Prostate; Prostate cancer; Taxane; TRAIL

Indexed keywords

EID: 75349090454     PISSN: 20804806     EISSN: 20804873     Source Type: Journal    
DOI: 10.5173/ceju.2009.01.art7     Document Type: Article

References (31)

1. Aus G, Abbou CC, Heidenreich A et al: Guidelines on prostate cancer. Eur Urol 2004; 41; 105-112.
2. Dobruch J, Borówka A, Antoniewicz AA, Chłosta P: Epidemiologia raka gruczołu krokowego. Urol Pol 2005; 1; 26-30.
3. Landis SH; Murray T, Bolden S, Wingo PA: Cancer Statistics. CA Cancer J Clin 1999; 49: 8-31.
4. Garmey EG, Sartor O, Halabi S, Vogelzang NJ: Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 2008; 6; 118-132.
5. Mancuso A, Qudard S, Sternberg CN: Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol 2007; 61; 176-185.
6. Obasaju C, Hudes GR: Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001; 15; 525-545.
7. Ramiah V, George DJ, Armstrong AJ: Clinical endpoints for drug development in prostate cancer. Curr Opin Urol 2008; 18; 303-308.
8. Stein CA: Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999; 26; 3-7.
9. Almasan A, Ashkenazi A: Apo2L/TRAIL: apoptosis signaling, biology and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14; 337-348.
10. Ashkenazi A, Pai R, Fong S et al: Safety and antitumor activity of recombinant Apo2 ligand. J Clin Invest 1999; 104; 155-162.
11. Kelley SK, Harris LA, Xie D et al: Pre-clinical studies to predict the disposition of Apo2L/ tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299; 31-38.
12. Zhang L, Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12; 228-227.
13. Duiker EW, Mom CH, Jong S et al: The clinical trail of TRAIL. Eur J Cancer 2006; 42; 2233-2240.
14. Shankar S, Srivastava RK: Enhancement oh therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004; 7; 139-156.
15. Szliszka E, Majcher A, Domino M et al: Cytotoksyczne działanie ligandu czynnika martwicy nowotworu indukuja{ogonek}cego apoptoze (TRAIL) na komórki raka pe{ogonek}cherza moczowego po zastosowaniu wybranych cytostatyków. Urol Pol 2007; 2; 138-142.
16. Szliszka E, Czuba ZP, Jernas et al: Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Mol Sci 2008; 9; 56-64.
17. Wu XX, Ogawa O, Kaleki Y: TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 2004; 67; 365-583.
18. Stachurska A, Wronka M, Kowalczyńska HM: Rak gruczołu krokowego w badaniach in vitro: charakterystyka linii komórkowych PC3, DU145 i LNCaP. Urol Pol 2007; 3; 195-201.
19. Cell proliferation kit I (MTT). Instruction manual. Version 3 2003. Roche Applied Science, Germany.
20. Cytotoxicity detection kit (LDH). Instruction manual. Version 5 2004. Roche Applied Science, Germany.
21. Wit R: Chemotherapy in hormone-refractory prostate cancer. BJU Int 2008; 101; 11-15.
22. Muenchen HJ, Poncza PJ, Pienta KJ: Different docetaxel-induced apoptotic pathways are present in prostate cancer. Urology 2001; 57; 366-370.
23. Nimmanapalli R, Perkins CL, Orlando M et al: Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptor 4 and 5 protein levels. Cancer Res 2001; 61; 759-763.
24. Asakuma J, Sumitomo M, Asano T, Hayakawa M: Selective Akt inactivation and tumor necrosis factor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 2003; 63; 1365-1370.
25. Lee KH, Yim EK, Kim CJ et al: Proteomic analysis of anticancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol 2005; 98; 45-53.
26. Shankar S, Chen X, Srivastava RK: Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vivo and in vitro. Prostate 2005; 62; 165-186.
27. Fan QL, Zou WY, Song LH, Wei W: Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemother Pharmacol 2005; 55; 189-196.
28. Yoo J, Park SS, Lee YJ: Pretreatment of docetaxel enhanced TRAIL-mediated apoptosis in prostate cancer cells. J Cell Biochem 2008; 104; 1636-1646.
29. Kim M, Liao J, Dowling ML et al: TRAIL inactivates the mitotic checkpoints and potentiates death induces by microtubule-targeting agents in human cancer cells. Cancer Res 2008; 68; 3440-3449.
30. Odoux C, Albers A: Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy. Vitam Horm 2004; 67; 385-407.
31. Vaishampayan U, Parchment RE, Jasti BR, Hussain M: Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 1999; 54; 22-29.